07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Isarna Therapeutics, Autotelic deal

Autotelic purchased worldwide rights to Isarna’s trabedersen, an antisense oligonucleotide targeting transforming growth factor (TGF) beta 2 (TGFB2) . The product was in Phase III testing to treat recurrent high-grade glioma. The partners did not...